Treatment of Human Brucellosis with Rifampin plus Minocycline
- 1 January 2003
- journal article
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 15 (3) , 248-252
- https://doi.org/10.1179/joc.2003.15.3.248
Abstract
In order to evaluate the efficacy and tolerability of a high intravenous dose of rifampin plus oral minocycline (administered daily for 3 weeks) for the treatment of acute brucellosis, we retrospectively reviewed the outcome of 239 consecutive patients (135 adults and 104 children) diagnosed and treated over a 17-year period in Italy. The combination used resulted in 100% response and a relapse rate lower than 2%. Fifty-two (30 adults and 22 children) (29.8%) complained of mild adverse effects including an increase in aspartate aminotransferase (>250 IU) observed in 12 cases and considered related to rifampin and in 11 cases a reversible hyperpigmentation of the tongue attributed to minocycline. A randomized prospective comparative study should be performed to confirm our encouraging results.Keywords
This publication has 8 references indexed in Scilit:
- Clinical manifestations, complications and treatment of brucellosis: a retrospective evaluation of 480 patientsMedecine Et Maladies Infectieuses, 2002
- In Vitro Activities of Antibiotics Alone and in Combination against Brucella melitensis at Neutral and Acidic pHsAntimicrobial Agents and Chemotherapy, 1999
- Minocycline-Induced PigmentationDrug Safety, 1998
- An Overview of Human BrucellosisClinical Infectious Diseases, 1995
- The Biogenesis of LysosomesAnnual Review of Cell Biology, 1989
- In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazoleAntimicrobial Agents and Chemotherapy, 1982
- Brucellosis treated with rifampicin.Archives of Disease in Childhood, 1980
- Metabolism and tissue distribution of radioisotopically labeled minocyclineToxicology and Applied Pharmacology, 1967